Tellus Therapeutics, Inc

tellus therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. tellus' lead candidate, tt-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal models of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.